Hemab Therapeutics
COAG----
All Shareholders
Shareholder Type
- VC/PE firms48.49%
- Institutions44.28%
- Hedge funds6.96%
- Individuals & Insiders0.26%
Major Shareholders
| Shareholder | |||||
|---|---|---|---|---|---|
RA Capital Management, L.P. | 16.72% | 7.81M | 0.91% | +2.97M | |
Access Biotechnology | 10.44% | 4.88M | 3.32% | +1.10M | |
Novo Holdings A/S | 8.95% | 4.18M | 6.28% | +0 | |
FMR LLC | 7.92% | 3.70M | -- | +3.70M | |
Capital Research and Management Company | 7.72% | 3.60M | 0.15% | +1.45M | |
Deep Track Capital, LP | 7.71% | 3.60M | 0.28% | +1.41M | |
Avoro Capital Advisors LLC | 7.06% | 3.30M | 0.51% | +1.50M | |
Sofinnova Partners SAS | 5.38% | 2.51M | 3.27% | +137.50K | |
Artal Group S.A. | 4.91% | 2.30M | 0.45% | +208.20K | |
Odlander, Fredrikson & Co. AB | 4.06% | 1.89M | 2.85% | +0 | |
Bain Capital Life Sciences Investors, LLC | 3.53% | 1.65M | -- | +1.65M | |
JP Morgan Asset Management | 2.43% | 1.13M | -- | +1.13M | |
Vanguard Capital Management, LLC | 1.91% | 893.26K | -- | +893.26K | |
T. Rowe Price Group, Inc. | 1.60% | 746.04K | -- | +746.04K | |
Driehaus Capital Management LLC | 1.53% | 715.79K | -- | +715.79K | |
Rock Springs Capital Management LP | 1.23% | 575.43K | -- | +575.43K | |
Bellevue Asset Management AG | 1.18% | 550.00K | -- | +550.00K | |
Citadel Advisors LLC | 1.12% | 523.45K | -- | +523.45K | |
BlackRock, Inc. | 0.61% | 283.83K | -- | +283.83K | |
Deerfield Management Company, L.P. | 0.59% | 275.00K | -- | +275.00K |